EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 350 filers reported holding EXELIXIS INC in Q4 2020. The put-call ratio across all filers is 2.32 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $72,883,734 | +16.4% | 3,335,640 | +1.8% | 0.02% | +16.7% |
Q2 2023 | $62,629,586 | -0.3% | 3,277,320 | +1.2% | 0.02% | -5.3% |
Q1 2023 | $62,846,649 | +15.9% | 3,237,849 | -4.2% | 0.02% | +11.8% |
Q4 2022 | $54,226,460 | +6.0% | 3,380,702 | +3.6% | 0.02% | -5.6% |
Q3 2022 | $51,150,000 | -19.6% | 3,262,102 | +6.8% | 0.02% | -18.2% |
Q2 2022 | $63,581,000 | -5.0% | 3,053,793 | +3.4% | 0.02% | +10.0% |
Q1 2022 | $66,938,000 | +35.2% | 2,952,703 | +9.0% | 0.02% | +33.3% |
Q4 2021 | $49,526,000 | -8.4% | 2,709,250 | +5.9% | 0.02% | -16.7% |
Q3 2021 | $54,092,000 | +76.6% | 2,558,760 | +52.2% | 0.02% | +80.0% |
Q2 2021 | $30,638,000 | -14.5% | 1,681,527 | +6.0% | 0.01% | -23.1% |
Q1 2021 | $35,828,000 | +16.2% | 1,586,009 | +3.3% | 0.01% | +8.3% |
Q4 2020 | $30,823,000 | -16.7% | 1,535,772 | +1.4% | 0.01% | -29.4% |
Q3 2020 | $37,023,000 | +4.8% | 1,514,203 | +1.7% | 0.02% | 0.0% |
Q2 2020 | $35,339,000 | +41.5% | 1,488,583 | +2.7% | 0.02% | +13.3% |
Q1 2020 | $24,968,000 | -0.2% | 1,449,933 | +2.1% | 0.02% | +15.4% |
Q4 2019 | $25,014,000 | -1.4% | 1,419,582 | -1.0% | 0.01% | -13.3% |
Q3 2019 | $25,361,000 | -11.0% | 1,433,993 | +7.6% | 0.02% | -11.8% |
Q2 2019 | $28,480,000 | -6.2% | 1,332,707 | +4.5% | 0.02% | -10.5% |
Q1 2019 | $30,349,000 | +30.4% | 1,275,137 | +7.8% | 0.02% | +5.6% |
Q4 2018 | $23,278,000 | +14.8% | 1,183,381 | +3.5% | 0.02% | +28.6% |
Q3 2018 | $20,271,000 | -7.6% | 1,143,910 | +12.2% | 0.01% | -12.5% |
Q2 2018 | $21,936,000 | +1.9% | 1,019,297 | +4.9% | 0.02% | -5.9% |
Q1 2018 | $21,521,000 | -30.8% | 971,567 | -5.0% | 0.02% | -32.0% |
Q4 2017 | $31,098,000 | +25.8% | 1,022,928 | +0.2% | 0.02% | +13.6% |
Q3 2017 | $24,727,000 | +17.3% | 1,020,479 | +19.3% | 0.02% | +10.0% |
Q2 2017 | $21,075,000 | -16.4% | 855,640 | -26.5% | 0.02% | -20.0% |
Q1 2017 | $25,224,000 | +87.5% | 1,163,989 | +29.0% | 0.02% | +66.7% |
Q4 2016 | $13,451,000 | +24.6% | 902,095 | +6.9% | 0.02% | +15.4% |
Q3 2016 | $10,793,000 | +73.6% | 843,827 | +6.0% | 0.01% | +62.5% |
Q2 2016 | $6,217,000 | +99.1% | 796,015 | +2.0% | 0.01% | +100.0% |
Q1 2016 | $3,122,000 | -27.5% | 780,493 | +2.2% | 0.00% | -33.3% |
Q4 2015 | $4,307,000 | +7.4% | 763,590 | +6.9% | 0.01% | 0.0% |
Q3 2015 | $4,009,000 | +67.5% | 714,544 | +12.3% | 0.01% | +100.0% |
Q2 2015 | $2,393,000 | +50.7% | 636,307 | +3.0% | 0.00% | +50.0% |
Q1 2015 | $1,588,000 | +118.7% | 617,725 | +22.7% | 0.00% | +100.0% |
Q4 2014 | $726,000 | -3.5% | 503,513 | +2.5% | 0.00% | 0.0% |
Q3 2014 | $752,000 | -56.1% | 491,435 | -2.7% | 0.00% | -66.7% |
Q2 2014 | $1,713,000 | -4.6% | 505,077 | -0.4% | 0.00% | 0.0% |
Q1 2014 | $1,795,000 | -38.7% | 506,853 | +6.2% | 0.00% | -50.0% |
Q4 2013 | $2,926,000 | +12.4% | 477,249 | +8.6% | 0.01% | +20.0% |
Q3 2013 | $2,603,000 | +33.8% | 439,569 | +5.3% | 0.01% | +25.0% |
Q2 2013 | $1,946,000 | – | 417,555 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |